Ipsen's Fidrisertib Fails Primary Endpoint in Pivotal Phase II FALKON Trial for Rare Bone Disease FOP on December 19, 2025 Clinical Trials FALKON Fibrodysplasia Ossificans Progressiva fidrisertib Heterotopic Ossification Ipsen Phase II Failure +
Regeneron Prepares U.S. Submission for Garetosmab After Breakthrough Phase III Result in Ultra-Rare FOP on September 18, 2025 bone lesion prevention fibrodysplasia Fibrodysplasia Ossificans Progressiva Garetosmab Infrequent OPTIMA trial ossificans Phase III progressiva Regeneron +